二皮瑞丁通道阻塞剂和脏结果
Matthew F Blum1, Aditya Surapaneni2, Alexander Chang3
1Division of Nephrology, Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA. mblum@medicine.wisc.edu.
Journal of general internal medicine
|April 19, 2024
概括
二皮瑞丁通道阻断剂 (DCCBs) 增加了白蛋白尿风险. 将DCCB与氨酸-血管新生素系统 (RAS) 阻塞结合起来,可以预防功能衰竭,特别是在没有RAS阻塞的患者中.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 基胺酸通道阻断剂 (DCCBs) 可能会对功能产生负面影响.
- 之前的研究表明,DCCB使用与白尿增加之间存在关联.
研究的目的:
- 评估启动DCCB和发展白蛋白尿或功能衰竭与替代疗法 (KFRT) 之间的联系.
- 为了调查氨酸-血管酶系统 (RAS) 阻塞是否会改变这些关联.
主要方法:
- 使用电子健康记录数据进行的目标试验仿真研究.
- 包括开始使用DCCB或 thiazides (活性比较剂) 且没有严重的白蛋白尿或KFRT的患者.
- 使用治疗权重和考克斯回归的逆概率来分析结果.
主要成果:
- 与 thiazides 相比,DCCB 启动与严重白蛋白尿症的风险更高有关 (HR,1.29;95% CI,1.16-1.43).
- 在没有RAS阻塞的患者中,KFRT的风险增加 (HR,1.66;95% CI,1.19-2.31) 但当RAS阻塞存在时没有.
- RAS阻断减轻了与DCCB相关的白蛋白尿和KFRT风险 (相互作用的P分别为<0.001和P=0.005).
结论:
- 二皮里丁通道阻断剂与白蛋白尿和功能衰竭的风险增加有关.
- 同时使用DCCB和RAS阻塞可能会防止不良结局.
相关概念视频
Antihypertensive Drugs: Action of Calcium Channel Blockers
513
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
513
Antihypertensive Drugs: Potassium-Sparing Diuretics
531
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
531
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832
Antihypertensive Drugs: Thiazide-Class Diuretics
620
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
620
Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
498
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
498


